These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30068530)

  • 1. Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.
    Janovick JA; Spicer TP; Bannister TD; Smith E; Ganapathy V; Scampavia L
    Biochem J; 2018 Sep; 475(18):2941-2953. PubMed ID: 30068530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
    J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus.
    Smith E; Janovick JA; Bannister TD; Shumate J; Scampavia L; Conn PM; Spicer TP
    J Biomol Screen; 2016 Sep; 21(8):824-31. PubMed ID: 27280550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
    Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
    J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.
    Janovick JA; Spicer TP; Bannister TD; Scampavia L; Conn PM
    PLoS One; 2017; 12(8):e0181830. PubMed ID: 28767678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
    Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.
    Janovick JA; Spicer TP; Smith E; Bannister TD; Kenakin T; Scampavia L; Conn PM
    Mol Cell Endocrinol; 2016 Oct; 434():176-85. PubMed ID: 27389877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
    Erdélyi LS; Balla A; Patócs A; Tóth M; Várnai P; Hunyady L
    Mol Endocrinol; 2014 May; 28(5):634-43. PubMed ID: 24628417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
    Ando F; Mori S; Yui N; Morimoto T; Nomura N; Sohara E; Rai T; Sasaki S; Kondo Y; Kagechika H; Uchida S
    Nat Commun; 2018 Apr; 9(1):1411. PubMed ID: 29650969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
    Los EL; Deen PM; Robben JH
    J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
    Robben JH; Deen PM
    BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
    Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
    J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
    Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
    Rochdi MD; Vargas GA; Carpentier E; Oligny-Longpré G; Chen S; Kovoor A; Gitelman SE; Rosenthal SM; von Zastrow M; Bouvier M
    Mol Pharmacol; 2010 May; 77(5):836-45. PubMed ID: 20159941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
    Robben JH; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
    Miyakoshi M; Kamoi K; Uchida S; Sasaki S
    Endocr J; 2003 Dec; 50(6):809-14. PubMed ID: 14709855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V2 vasopressin receptor mutations.
    Makita N; Manaka K; Sato J; Iiri T
    Vitam Horm; 2020; 113():79-99. PubMed ID: 32138955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A low-affinity vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus.
    Yokoyama K; Yamauchi A; Izumi M; Itoh T; Ando A; Imai E; Kamada T; Ueda N
    J Am Soc Nephrol; 1996 Mar; 7(3):410-4. PubMed ID: 8704106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.